Let's hope so. The PK/PD data doesn't seem to be a major PPS mover at this point because it simply supports a claim that's already been made public in many, many PRs. Had they waited until the ASM to announce the success of Pro 140 as a monotherapy combined with the PK/PD date, it would be a different story.
Market Data 
Markets 
AI
